Table 1.
Samples | Clean Reads | Total Reads | GC Content | %≥Q30 |
---|---|---|---|---|
T-4h-1 | 21,547,204 | 43,094,408 | 42.41% | 90.35% |
T-4h-2 | 22,512,422 | 45,024,844 | 39.92% | 90.86% |
T-4h-3 | 24,148,619 | 48,297,238 | 42.26% | 90.63% |
T-8h-1 | 38,754,441 | 77,508,882 | 42.62% | 91.54% |
T-8h-2 | 24,002,510 | 48,005,020 | 41.32% | 90.02% |
T-8h-3 | 22,122,639 | 44,245,278 | 39.74% | 91.17% |
T-16h-1 | 23,547,935 | 47,095,870 | 42.30% | 91.52% |
T-16h-2 | 22,069,447 | 44,138,894 | 40.20% | 91.42% |
T-16h-3 | 22,239,750 | 44,479,500 | 42.57% | 90.65% |
T-24h-1 | 25,170,248 | 50,340,496 | 42.54% | 89.66% |
T-24h-2 | 26,533,253 | 53,066,506 | 41.57% | 90.98% |
T-24h-3 | 22,340,639 | 44,681,278 | 41.71% | 91.47% |
W-4h-1 | 24,392,303 | 48,784,606 | 41.81% | 90.56% |
W-4h-2 | 25,368,822 | 50,737,644 | 41.82% | 90.73% |
W-4h-3 | 23,584,970 | 47,169,940 | 41.91% | 90.75% |
W-8h-1 | 21,703,936 | 43,407,872 | 44.07% | 90.44% |
W-8h-2 | 27,725,344 | 55,450,688 | 44.13% | 89.82% |
W-8h-3 | 31,397,538 | 62,795,076 | 44.10% | 90.28% |
W-16h-1 | 21,417,269 | 42,834,538 | 40.71% | 89.96% |
W-16h-2 | 24,218,605 | 48,437,210 | 39.80% | 91.23% |
W-16h-3 | 20,903,499 | 41,806,998 | 39.35% | 90.55% |
W-24h-1 | 22,905,768 | 45,811,536 | 42.11% | 91.31% |
W-24h-2 | 23,248,816 | 46,497,632 | 40.75% | 90.19% |
W-24h-3 | 20,628,223 | 41,256,446 | 41.82% | 91.05% |
T: M. anisopliae treatment group; W: Control group.